GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research > CVD Prevention and Risk Factors

Photo for HOPE – 3 Passive Follow up

HOPE – 3 Passive Follow up

Official Title

Heart Outcomes Prevention Evaluation-3 Passive Follow-Up

Status

Ongoing

Overview

Substantial reductions in cholesterol and blood pressure levels for an average of at least five years may lead to sustained long-term benefits, extending beyond the in-trial period, even without further treatments. Participants enrolled in the clinical phase of HOPE-3 will be followed passively (i.e. off study drug) after completion of the trial. During the passive follow-up period, there will be no protocol-mandated therapies and the primary care physicians will determine treatment of all study participants based on their interpretation of the available evidence.

Study Design

Follow-up will conducted yearly by direct or telephone contact

Primary Endpoint

Occurrence of major CV events

Number of Patients

11134

Number of Sites

229

Number of Countries

21

Study Period

2016-2021

Principal Investigator

Salim Yusuf, Eva Lonn

Program Manager

Jackie Bosch

Research Coordinator

Kelly Kewell